Corcept Therapeutics Incorporated (CORT): Price and Financial Metrics


Corcept Therapeutics Incorporated (CORT): $20.04

-1.22 (-5.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CORT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

CORT POWR Grades


  • Quality is the dimension where CORT ranks best; there it ranks ahead of 98.71% of US stocks.
  • CORT's strongest trending metric is Stability; it's been moving up over the last 51 weeks.
  • CORT ranks lowest in Momentum; there it ranks in the 9th percentile.

CORT Stock Summary

  • The ratio of debt to operating expenses for Corcept Therapeutics Inc is higher than it is for about only 5.22% of US stocks.
  • CORT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 7.58% of US stocks.
  • With a year-over-year growth in debt of -55.52%, Corcept Therapeutics Inc's debt growth rate surpasses just 7.63% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Corcept Therapeutics Inc, a group of peers worth examining would be UTHR, AMPH, PDFS, CLSN, and MTSI.
  • CORT's SEC filings can be seen here. And to visit Corcept Therapeutics Inc's official web site, go to www.corcept.com.

CORT Valuation Summary

  • In comparison to the median Healthcare stock, CORT's EV/EBIT ratio is 24.23% lower, now standing at 22.2.
  • CORT's EV/EBIT ratio has moved up 50.1 over the prior 212 months.
  • CORT's price/sales ratio has moved NA NA over the prior 212 months.

Below are key valuation metrics over time for CORT.

Stock Date P/S P/B P/E EV/EBIT
CORT 2021-08-31 7.2 4.7 25.3 22.2
CORT 2021-08-30 7.3 4.8 25.6 22.5
CORT 2021-08-27 7.3 4.8 25.6 22.5
CORT 2021-08-26 7.1 4.7 25.1 22.0
CORT 2021-08-25 7.1 4.7 25.1 22.1
CORT 2021-08-24 7.1 4.7 25.1 22.1

CORT Growth Metrics

  • The 2 year revenue growth rate now stands at 76.95%.
  • Its 5 year net cashflow from operations growth rate is now at 4555.11%.
  • Its 3 year net income to common stockholders growth rate is now at 4873.01%.
CORT's revenue has moved up $91,840,000 over the prior 30 months.

The table below shows CORT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 343.087 135.276 97.607
2021-03-31 340.064 144.123 99.411
2020-12-31 353.874 151.97 106.011
2020-09-30 356.034 165.353 109.398
2020-06-30 351.212 173.336 114.113
2020-03-31 334.904 145.705 105.972

CORT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CORT has a Quality Grade of A, ranking ahead of 98.84% of graded US stocks.
  • CORT's asset turnover comes in at 0.616 -- ranking 53rd of 680 Pharmaceutical Products stocks.
  • OTIC, ABT, and AVDL are the stocks whose asset turnover ratios are most correlated with CORT.

The table below shows CORT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.616 0.985 0.237
2021-03-31 0.631 0.985 0.248
2020-12-31 0.691 0.984 0.312
2020-09-30 0.754 0.984 0.345
2020-06-30 0.816 0.983 0.413
2020-03-31 0.862 0.982 0.432

CORT Price Target

For more insight on analysts targets of CORT, see our CORT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.25 Average Broker Recommendation 1.75 (Moderate Buy)

CORT Stock Price Chart Interactive Chart >

Price chart for CORT

CORT Price/Volume Stats

Current price $20.04 52-week high $31.18
Prev. close $21.26 52-week low $16.52
Day low $20.01 Volume 508,500
Day high $21.49 Avg. volume 542,821
50-day MA $20.70 Dividend yield N/A
200-day MA $23.10 Market Cap 2.32B

Corcept Therapeutics Incorporated (CORT) Company Bio


Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders. The company was founded in 1998 and is based in Menlo Park, California.


CORT Latest News Stream


Event/Time News Detail
Loading, please wait...

CORT Latest Social Stream


Loading social stream, please wait...

View Full CORT Social Stream

Latest CORT News From Around the Web

Below are the latest news stories about Corcept Therapeutics Inc that investors may wish to consider to help them evaluate CORT as an investment opportunity.

NASDAQ:CORT Shareholder Alert: Update in Lawsuit Against Corcept Therapeutics Announced by Shareholders Foundation

SAN DIEGO, CA / ACCESSWIRE / October 12, 2021 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in (NASDAQ:CORT) shares.

Yahoo | October 12, 2021

Corcept Therapeutics' (NASDAQ:CORT) 27% CAGR outpaced the company's earnings growth over the same five-year period

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Yahoo | October 12, 2021

Chief Commercial Officer Of Corcept Therapeutics Trades $580K In Company Stock

Sean Maduck, Chief Commercial Officer at Corcept Therapeutics (NASDAQ:CORT), made a large buy and sell of company shares on October 5, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Sean Maduck exercised options to purchase 25,000 Corcept Therapeutics shares at a price of $3.29 per share for a total of $82,250 on October 5. They then sold their shares on multiple transactions in the open market. They sold at a price of $

Yahoo | October 6, 2021

Moore Kuehn, PLLC Encourages Investors of Corcept Therapeutics, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - October 4, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Corcept Therapeutics, Inc. (NASDAQ: CORT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Corcept insiders caused the company to make false and/or misleading statements and/or failed to disclose that: (1) that the company had improperly paid doctors to promote its ...

Yahoo | October 4, 2021

SHAREHOLDER ALERT: Morris Kandinov Investigating LDI, CCL, CORT, and MIDQX; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of loanDepot, Inc., Carnival Corporation and plc, Corcept Therapeutics, Inc., and DWS ESG Core Equity Fund. If you are a current owner of shares of any of these stocks, contact [email protected] or call (619) 708-3993. loanDepot, Inc. (NYSE: LDI) Accused of Misleading Investors Morris Kandinov announces that a class action lawsuit has been filed against l

Yahoo | September 30, 2021

Read More 'CORT' Stories Here

CORT Price Returns

1-mo -2.29%
3-mo -2.15%
6-mo -13.55%
1-year 11.33%
3-year 64.67%
5-year 198.21%
YTD -23.39%
2020 116.20%
2019 -9.43%
2018 -26.02%
2017 148.76%
2016 45.78%

Continue Researching CORT

Here are a few links from around the web to help you further your research on Corcept Therapeutics Inc's stock as an investment opportunity:

Corcept Therapeutics Inc (CORT) Stock Price | Nasdaq
Corcept Therapeutics Inc (CORT) Stock Quote, History and News - Yahoo Finance
Corcept Therapeutics Inc (CORT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9619 seconds.